PTGX - Protagonist Therapeutics, Inc

105.89
0.420   0.397%

Share volume: 494,720
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$105.47
0.42
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 9%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.08%
1 Month
7.46%
3 Months
24.89%
6 Months
44.07%
1 Year
130.95%
2 Year
297.93%
Key data
Stock price
$105.89
P/E Ratio 
0.00
DAY RANGE
$103.64 - $106.45
EPS 
-$2.05
52 WEEK RANGE
$41.28 - $107.84
52 WEEK CHANGE
$129.40
MARKET CAP 
5.460 B
YIELD 
N/A
SHARES OUTSTANDING 
63.809 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$738,217
AVERAGE 30 VOLUME 
$766,714
Company detail
CEO: Dinesh V. Patel
Region: US
Website: protagonist-inc.com
Employees: 120
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.

Recent news